The Role of the Health Insurance Industry in Perpetuating Suboptimal Pain Management

Pain Medicine

Volumn 12, Issue 3, 2011, Pages 415-426

  Schatman, Michael E ^a  

^a Foundation for Ethics in Pain Care   (United States)

Author keywords

Business Ethic; Claim Denial; Evidence Basis; Health Insurance; Medical Ethics; Treatment Delay

Indexed keywords

ARTICLE; CHRONIC PAIN; COST CONTROL; HEALTH CARE INDUSTRY; HEALTH INSURANCE; HUMAN; PROFIT; REIMBURSEMENT;

EID: 79953042374     PISSN: 15262375     EISSN: 15264637     Source Type: Journal    
DOI: 10.1111/j.1526-4637.2011.01061.x     Document Type: Article

References (130)

1. Henry J. Kaiser family foundation. Kaiser health tracking poll. 2009. Available at: (accessed December 2010).
2. Institute of Medicine. Origins and evolution of employment-based health benefits. In: Field MJ, Shapiro HT, eds. Employment and Health Benefits: A Connection at Risk. Washington, DC: National Academy Press; 1993:49-86.
3. Edelberg C. Emergency department coding and billing. Emerg Med Clin North Am 2004;22:131-51.
4. Employee Benefit Research Institute. History of health insurance benefits. 2002. Available at: (accessed July 2010).
5. Light DW. Ironies of success: A new history of the American health care "system". J Health Soc Behav 2004;45(suppl):1-24.
6. Quadagno A. Why the United States has no national health insurance: Stakeholder mobilization against the welfare state, 1945-1996. J Health Soc Behav 2004;45(suppl):25-44.
7. Helms RB. Tax policy and the history of the health insurance industry. 2008. Available at: (accessed July 2010).
8. Frech HE. Competition & Monopoly in Medical Care. Washington, DC: AEI Press; 1996.
9. Law S. Blue Cross: What Went Wrong? New Haven, CT: Yale University Press; 1974.
10. Brown LD. The metamorphosis: Conversion in historical context. Bull N Y Acad Med 1997;74:238-47.
11. Schlesinger M, Marmor TR, Smithey R. Nonprofit and for-profit medical care: Shifting roles and implications for health policy. J Health Polit Policy Law 1987;12:427-57.
12. Starr P. The Social Transformation of American Medicine. New York: Basic Books; 1982.
13. Glied SA. Health insurance and market failure since Arrow. J Health Polit Policy Law 2001;26:957-65.
14. Scofea LA. The development and growth of employer-provided health insurance. Mon Labor Rev 1994;117:3-10.
15. Moseley GB. The U.S. healthcare non-system, 1908-2008. Virtual Mentor 2008;10:324-31.
16. Kraus N, Porter M, Ball P. The InterStudy Edge. Managed Care: A Decade in Review, 1980-1990. St Paul, MN: InterStudy Publications; 1999.
17. Gray BH. Introduction: Overview of the conversion phenomenon. Bull N Y Acad Med 1997;74:175-9.
18. Himmelstein DU, Woolhandler S, Hellander I, Wolfe SM. Quality of care in investor-owned vs not-for-profit HMOs. JAMA 1999;282:159-63.
19. Tu HT, Reschovsky JD. Assessments of medical care by enrollees in for-profit and nonprofit health maintenance organizations. N Engl J Med 2002;346:1288-93.
20. Alliance for Advancing Nonprofit Healthcare. Nonprofit health plans continue superiority in member-satisfaction rankings. Available at: (accessed July 2010).
21. Robinson JC. The end of managed care. JAMA 2001;285:2622-8.
22. Kongstvedt PR. Managed Care: What It Is and How It Works, 3rd edition. Sudbury, MA: Jones and Bartlett Publishers; 2009.
23. Lagoe R, Aspling DL, Westert GP. Current and future developments in managed care in the United States and implications for Europe. Health Res Policy Syst 2005;3:4-12.
24. Fish L, Nicholson BD. The payer side: Patient outcomes and cost. Am J Ther 2008;15(suppl 1):S20-3.
25. Brosnan D. Open season in Sacramento. West J Emerg Med 2009;10:3. Available at: (accessed November 2010).
26. Schatman ME. The demise of multidisciplinary pain management clinics? Pract Pain Manag 2006;6:30-41.
27. Schatman ME. The demise of the multidisciplinary chronic pain management clinic: Bioethical perspectives on providing optimal treatment when ethical principles collide. In: Schatman ME, ed. Ethical Issues in Chronic Pain Management. New York: Informa Healthcare; 2007:43-62.
28. Flor H, Fydrich T, Turk D. Efficacy of multidisciplinary pain treatment centers: A meta-analytic review. Pain 1992;49:221-30.
29. Turk DC, Okifuji A. Treatment of chronic pain patients: Clinical outcomes, cost-effectiveness, and cost-benefits of multidisciplinary pain centers. Crit Rev Phys Rehabil Med 1998;10:181-208.
30. Okifuji A, Turk DC, Kalauoklani D. Clinical outcome and economic evaluation of multidisciplinary pain centers. In: Block AR, Kramer EF, Fernandez E, eds. Handbook of Pain Syndromes: Biopsychosocial Perspectives. Mahwah, NJ: Lawrence Erlbaum Associates; 1999:77-97.
31. Guzman J, Esmail R, Karjalainen K, etal. Multidisciplinary rehabilitation for chronic low back pain: A systematic review. BMJ 2001;322:1511-6.
32. Turk DC. Clinical effectiveness and cost-effectiveness of treatments for patients with chronic pain. Clin J Pain 2002;18:355-65.
33. Guzman J, Esmail R, Karjalainen K, etal. Multidisciplinary bio-psycho-social rehabilitation for chronic low back pain. Cochrane Database Syst Rev 2002;(1):CD000963.
34. Schonstein E, Kenny DT, Keating J, Kord BW. Work conditioning, work hardening, and functional restoration for workers with back and neck pain. Cochrane Database Syst Rev 2003;(1):CD001822.
35. Turk DC, Swanson K. Efficacy and cost-effectiveness treatment for chronic pain: An analysis and evidence-based synthesis. In: Schatman ME, Campbell A, eds. Chronic Pain Management: Guidelines for Multidisciplinary Program Development. New York: Informa Healthcare; 2007:15-38.
36. Patrick LE, Altmaier EM, Found EM. Long-term outcomes in multidisciplinary treatment of chronic low back pain: Results of a 13-year follow-up. Spine 2004;9:850-5.
37. Weir R, Browne GB, Tunks E, Gafni A, Roberts J. A profile of users of specialty pain clinic services: Predictors of use and cost estimates. J Clin Epidemiol 1992;45:1399-415.
38. Gatchel RJ, Okifuji A. Evidence-based scientific data documenting the treatment and cost-effectiveness of comprehensive pain programs for chronic nonmalignant pain. J Pain 2006;7:779-93.
39. Volinn E, Fargo JD, Fine PG. Opioid therapy for nonspecific low back pain and the outcome of chronic work loss. Pain 2009;142:194-201.
40. Franklin GM, Stover BD, Turner JA, Fulton-Kehoe D, Wickizer TM. Early opioid prescription and subsequent disability among workers with back injuries: The disability risk identification study cohort. Spine 2008;33:199-204.
41. Webster BS, Verma SK, Gatchel RJ. Relationship between early opioid prescribing for acute occupational low back pain and disability duration, medical costs, subsequent surgery and late opioid use. Spine 2007;32:2127-32.
42. Merza Z. Chronic use of opioids and the endocrine system. Horm Metab Res 2010;42:621-6.
43. Rhodin A, Stridsberg M, Gordh T. Opioid endocrinopathy: A clinical problem in patients with chronic pain and long-term oral opioid treatment. Clin J Pain 2010;26:374-80.
44. Cicero TJ, Wong G, Tian Y, etal. Co-morbidity and utilization of medical services by pain patients receiving opioid medications: Data from an insurance claims database. Pain 2009;144:20-7.
45. Ghate SR, Haroutiunian S, Winslow R, McAdam-Marx C. Cost and comorbidities associated with opioid abuse in managed care and Medicaid patients in the United States: A comparison of two recently published studies. J Pain Palliat Care Pharmacother 2010;24:251-8.
46. Schatman ME. Interdisciplinary chronic pain management: Perspectives on history, current status, and future viability. In: Ballantyne JC, Rathmell JP, Fishman SM, eds. Bonica's Management of Pain, 4th edition. Philadelphia, PA: Lippincott, Williams & Wilkins; 2010:1523-32.
47. Schatman ME, Sullivan J. Whither suffering? The potential impact of tort reform on the emotional and existential healing of traumatically injured chronic pain patients. Psychological Inj Law 2010;3:182-202.
48. Cohen B. Divided loyalties: How the Metlife v. Glenn standard discounts ERISA fiduciaries' conflicts of interest. Utah Law Rev 2009;3:955-92.
49. Pellino TA, Gordon DB, Dahl JL. The WPI's review of Wisconsin's managed care climate for pain management: Opportunities for improvement. WMJ 2006;105:27-31, 50.
50. Biddle J. Do high claim-denial rates discourage claiming? Evidence from workers compensation insurance. J Risk Insur 2001;68:631-58.
51. Dumit J. Illnesses you have to fight to get: Facts as forces in uncertain, emergent illnesses. Soc Sci Med 2006;62:577-90.
52. Melucci A. Challenging Codes: Collective Action in the Information Age. Cambridge: Cambridge University Press; 1996.
53. Holloway I, Sofaer-Bennett B, Walker J. The stigmatisation of people with chronic back pain. Disabil Rehabil 2007;29:1456-64.
54. LaChapelle DL, Lavoie S, Boudreau A. The meaning and process of pain acceptance: Perceptions of women living with arthritis and fibromyalgia. Pain Res Manag 2008;13:201-10.
55. Slade SC, Molloy E, Keating JL. Stigma experienced by people with nonspecific chronic low back pain: A qualitative study. Pain Med 2009;10:143-54.
56. Goldberg DS. Job and the stigmatization of chronic pain. Perspect Biol Med 2010;53:425-38.
57. Trueman DL. Pain management and managed care: Managing the system. In: Schatman ME, ed. Ethical Issues in Chronic Pain Management. New York: Informa Healthcare; 2007:207-21.
58. Gatchel RJ, Noe C, Gajraj N, etal. The negative impact on an interdisciplinary pain management program of insurance "treatment carve out" practices. J Workers Compens 2001;10:50-63.
59. Robbins H, Gatchel RJ, Noe C, etal. A prospective one-year outcome study of interdisciplinary chronic pain management: Compromising Its efficacy by managed care policies. Anesth Analg 2003;97:156-62.
60. Gatchel RJ, Kishino ND, Noe C. Carving-out services from multidisciplinary chronic pain management programs: Negative impact on therapeutic efficacy. In: Schatman ME, Campbell A, eds. Chronic Pain Management: Guidelines for Multidisciplinary Program Development. New York: Informa Healthcare; 2007:39-48.
61. Ross JS. Health reform redux: Learning from experience and politics. Am J Public Health 2009;99:779-86.
62. Wilsey BL, Fishman SM, Crandall M, Casamalhuapa C, Bertakis KD. A qualitative study of the barriers to chronic pain management in the ED. Am J Emerg Med 2008;26:255-63.
63. Mariner WK. Can consumer-choice plans satisfy patients? Problems with theory and practice in health insurance contracts. Brooklyn Law Rev 2004;69:485-542.
64. Sinnott P. Administrative delays and chronic disability in patients with acute occupational low back injury. J Occup Environ Med 2009;51:690-9.
65. Frank J, Sinclair S, Hogg-Johnson S, etal. Preventing disability from work-related low-back pain. New evidence gives new hope-if we can just get all the players onside. CMAJ 1998;158:1625-31.
66. Gallagher RM, Myers P. Referral delay in back pain patients on worker's compensation: Costs and policy implications. Psychosomatics 1996;37:270-84.
67. Mollborn S, Stepanikova I, Cook KS. Delayed care and unmet needs among health care system users: When does fiduciary trust in a physician matter? Health Serv Res 2005;40:1898-917.
68. McCracken LM, Klock PA, Mingay DJ, Asbury JK, Sinclair DM. Assessment of satisfaction with treatment for chronic pain. J Pain Symptom Manage 1997;14:292-9.
69. Dawson R, Spross JA, Jablonski ES, etal. Probing the paradox of patients' satisfaction with inadequate pain management. J Pain Symptom Manage 2002;23:211-20.
70. Margolis JM, Johnston SS, Chu BC, etal. Effects of a Medicaid prior authorization policy for pregabalin. Am J Manag Care 2009;15:e95-102.
71. Moore WJ, Newman RJ. Drug formulary restrictions as a cost-containment policy in Medicaid programs. J Law Econ 1993;36:71-97.
72. Smalley WE, Griffin MR, Fought RL, Sullivan L, Ray WA. Effect of a prior-authorization requirement on the use of nonsteroidal anti-inflammatory drugs by Medicaid patients. N Engl J Med 1995;332:1612-7.
73. Kotzan JA, McMillan JA, Jankel CA, Foster AL. Initial impact of a Medicaid prior authorization program for NSAID prescriptions. J Res Pharmcol Econ 1993;5:25-41.
74. Kulich RJ, Adolph M. Multidisciplinary chronic pain treatment: Minimizing financial risk. In: Schatman ME, Campbell A, eds. Chronic Pain Management: Guidelines for Multidisciplinary Program Development. New York: Informa Healthcare; 2007:241-62.
75. Sweet JJ, Moberg PJ, Suchy Y. Ten-year follow-up survey of clinical neuropsychologist: Part II. Private practice and economics. Clin Neuropsychol 2000;14:479-95.
76. Rogers R, Vitacco MJ. Forensic assessment of malingering and related response styles. In: Van Dorsten B, ed. Forensic Psychology: From Classroom to Courtroom. Boston, MA: Kluwer Academic/Plenum; 2002:83-104.
77. Faust D, Heard KV. Biased experts: Some practical suggestions for identifying and demonstrating unfair practices. In: Schultz IZ, Brady DO, eds. Psychological Injuries at Trial. Chicago, IL: American Bar Association; 2003:1706-39.
78. Schofferman J. Opinions and testimony of expert witnesses and independent medical evaluators. Pain Med 2007;8:376-82.
79. Baer MA. Opinion piece: Is an independent medical evaluation independent? Forensic Examiner 2005;14:33.
80. Rondinelli RD, Robinson JP, Scheer SJ, Weinstein SM. Industrial rehabilitation medicine. 4. Strategies for disability management. Arch Phys Med Rehabil 1997;78(suppl 1):S21-8.
81. Benner DE. Ethical dilemmas of chronic pain from a patient's perspective. In: Schatman ME, ed. Ethical Issues in Chronic Pain Management. New York: Informa Healthcare; 2007:15-32.
82. Loeser JD. Foreword. In: Schatman ME, Campbell A, eds. Chronic Pain Management: Guidelines for Multidisciplinary Program Development. New York: Informa Healthcare; 2007:iii-iv.
83. Joranson DE. Are health care reimbursement policies a barrier to acute and cancer pain management? J Pain Symptom Manage 1994;9:244-53.
84. Varela H. Dynamic Caims, July 2007-June 2010. Bridgewater, NJ: Wolters Kluwer Pharma Solutions; 2010.
85. Gore M, Sadosky A, Tai KS, Stacey B. A retrospective evaluation of the use of gabapentin and pregabalin in patients with post-herpetic neuralgia in usual-care settings. Clin Ther 2007;29:1655-70.
86. Perez C, Navarro A, Saldana MT, Masramon X, Rejas J. Pregabalin and gabapentin in matched patients with peripheral neuropathic pain in routine medical practice in a primary care setting: Findings from a cost-consequences analysis in a nested case-controlled study. Clin Ther 2010;32:1357-70.
87. Rodriguez MJ, Diaz S, Vera-Llonch M, Dukes E, Rejas J. Cost-effectiveness analysis of pregabalin versus gabapentin in the management of neuropathic pain due to diabetic polyneuropathy or post-herpetic neuralgia. Curr Med Res Opin 2007;23:2585-96.
88. Smith K, Roberts M. Sequential medication strategies for postherpetic neuralgia: A cost-effectiveness analysis. J Pain 2007;8:396-404.
89. Hempenstall K, Nurmikko TJ, Johnson RW, A'hern RP, Rice AS. Analgesic therapy in postherpetic neuralgia: A quantitative systematic review. PLoS Med 2005;2:e164.
90. Volpe FM. An 8-week open-label trial of duloxetine for comorbid major depressive disorder and chronic headache. J Clin Psychiatry 2008;69:1449-54.
91. Lunn MP, Hughes RA, Wiffen PJ. Duloxetine for treating painful neuropathy or chronic pain. Cochrane Database Syst Rev 2009;(4):CD007115.
92. Chappell AS, Desaiah D, Liu-Seifert H, etal. A double-blind, randomized, placebo-controlled study of the efficacy and safety of duloxetine for the treatment of chronic pain due to osteoarthritis of the knee. Pain Pract 2011;11:33-41.
93. Skljarevski V, Zhang S, Chappell AS, etal. Maintenance of effect of duloxetine in patients with chronic low back pain: A 41-week uncontrolled, dose-blinded study. Pain Med 2010;11:648-57.
94. Wright CL, Mist SD, Ross RL, Jones KD. Duloxetine for the treatment of fibromyalgia. Expert Rev Clin Immuol 2010;6:745-56.
95. Wu EQ, Birnbaum HG, Mareva MN, etal. Cost-effectiveness of duloxetine versus routine treatment for U.S. patients with diabetic peripheral neuropathic pain. J Pain 2006;7:399-407.
96. Wu N, Chen S, Boulanger L, etal. Duloxetine compliance and its association with healthcare costs among patients with diabetic peripheral neuropathic pain. J Med Econ 2009;12:192-202.
97. Ho KY, Tay W, Yeo MC, etal. Duloxetine reduces morphine requirements after knee replacement surgery. Br J Anaesth 2010;105:371-6.
98. Zhao Y, Wu N, Chen S, etal. Changes in opioid use and healthcare costs among U.S. patients with diabetic peripheral neuropathic pain treated with duloxetine compared to other therapies. Curr Med Res Opin 2010;26:2147-56.
99. Max MB, Lynch SA, Muir J, etal. Effects of desipramine, amitriptyline, and fluoxetine on pain in diabetic neuropathy. N Engl J Med 1992;326:1250-6.
100. Orbai AM, Meyerhoff JO. The effectiveness of tricyclic antidepressants on lumbar spinal stenosis. Bull NYU Hosp Jt Dis 2010;68:22-4.
101. Khawam EA, Laurencic G, Malone DA. Side effects of antidepressants: An overview. Cleve Clin J Med 2006;73:351-61.
102. Zin CS, Nissen LM, Smith MT, O'Callaghan JP, Moore BJ. An update on the pharmacological management of post-herpetic neuralgia and painful diabetic neuropathy. CNS Drugs 2008;22:417-42.
103. Bansal D, Bhansali A, Hota D, Chakrabarti A, Dutta P. Amitriptyline vs. pregabalin in painful diabetic neuropathy: A randomized double blind clinical trial. Diabet Med 2009;26:1019-26.
104. Arnold LM. Duloxetine and other antidepressants in the treatment of patients with fibromyalgia. Pain Med 2007;8(suppl 2):S63-74.
105. Katz NP, Sherburne S, Beach M, etal. Behavioral monitoring and urine toxicology testing in patients receiving long-term opioid therapy. Anesth Analg 2003;97:1097-102.
106. Manchikanti L, Manchukonda R, Damron KS, etal. Does adherence monitoring reduce controlled substance abuse in chronic pain patients? Pain Physician 2006;9:57-60.
107. Manchikanti L, Manchukonda R, Pampati V, etal. Does random urine drug testing reduce illicit drug use in chronic pain patients receiving opioids? Pain Physician 2006;9:123-9.
108. Goldberg KC, Simel DL, Oddone EZ. Effect of an opioid management system on opioid prescribing and unscheduled visits in a large primary care clinic. J Clin Outcomes Manag 2005;12:621-8.
109. Wiedemer NL, Harden PS, Arndt IO, Gallagher RM. The opioid renewal clinic: A primary care, managed approach to opioid therapy in chronic pain patients at risk for substance abuse. Pain Med 2007;8:573-84.
110. Couto JE, Romney MC, Leider HL, Sharma S, Goldfarb NI. High rates of inappropriate drug use in the chronic pain population. Popul Health Manag 2009;12:185-9.
111. Manchikanti L, Malla Y, Wargo BW, etal. Protocol for accuracy of point of care (POC) or in-office urine drug testing (immunoassay) in chronic pain patients: A prospective analysis of immunoassay and liquid chromatography tandem mass spectrometry. Pain Physician 2010;13:E1-22.
112. Benyamin RM, Datta S, Falco FJE. A perfect storm in interventional pain management: Regulated, but unbalanced. Pain Physician 2010;13:109-16.
113. Bair MJ, Krebs EE. Why is urine drug testing not used more often in practice. Pain Pract 2010;10:493-6.
114. Johnson PE, Dahlman G, Eng K, etal. NCCN oncology risk evaluation and mitigation strategies white paper: Recommendations for stakeholders. J Natl Compr Canc Netw 2010;8(suppl 7):S7-27.
115. Merskey H, Teasell RW. Problems with insurance-based research on chronic pain. Med Clin North Am 2007;91:31-43.
116. Sullivan MD, Loeser JD. The diagnosis of disability. Treating and rating disability in pain clinic. Arch Intern Med 1992;152:1829-35.
117. Miller CE. Arthritis and the role of the physician in nonmalignant pain and disability. J Health Soc Policy 2002;16:33-42.
118. Garber AM. Evidence-based coverage policy. Health Aff 2001;20:62-82.
119. Merskey H. Social influences on the concept of fibromyalgia. CNS Spectr 2008;13(suppl 5):18-21.
120. Russell IJ. Fibromyalgia syndrome: Approach to management. CNS Spectr 2008;13(suppl 5):27-33.
121. Staud R, Spaeth M. Psychophysical and neurochemical abnormalities of pain processing in fibromyalgia. CNS Spectr 2008;13(suppl 5):12-7.
122. Sipkoff M. Fibromyalgia coverage uneven despite recent drug approvals. Manag Care 2008;17:9-10.
123. Somerville MA. Death of pain: Pain, suffering, and ethics. In: Gebhart GF, Hammond DL, Jensen TS, eds. Progress in Pain Research and Management, Vol. 2. Seattle, WA: IASP Press; 1994:41-58.
124. Beauchamp TL, Childress JF. Principles of Biomedical Ethics, 5th edition. New York: Oxford University Press; 2001.
125. Pellegrino ED. The commodification of medical and health care: The moral consequences of a paradigm shift from a professional to a market ethic. J Med Philos 1999;24:243-66.
126. Giordano J, Schatman M. A crisis in pain care: An ethical analysis. Part 1. Facts, issues, and problems. Pain Physician 2008;11:483-90.
127. Giordano J, Schatman ME. A crisis in chronic pain care: An ethical analysis; Part 2. Proposed structure and function of an ethics of pain medicine. Pain Physician 2008;11:589-95.
128. Giordano J, Schatman ME. A crisis in chronic pain care: An ethical analysis. Part 3: Toward an integrative, multi-disciplinary pain medicine built around the needs of the patient. Pain Physician 2008;11:771-84.
129. Giordano J, Schatman ME, Hover G. Ethical insights to rapprochement in pain care: Bringing stakeholders together in the best interest(s) of the patient. Pain Physician 2009;12:265-75.
130. Health Care for America Now. Third-quarter profit reach $3.4 billion as health insurers cut spending on care, drop unprofitable members. Available at: (accessed November 2010).